New combo therapy aims to stop liver cancer from coming back
NCT ID NCT04962958
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether adding a targeted drug (Donafenib) and chemotherapy directly into the liver's blood supply can prevent liver cancer from returning after surgery. It includes adults with a single large tumor (≥5 cm) and microscopic blood vessel invasion, who are at high risk of recurrence. Participants receive the combined treatment for up to 2 years, and researchers track how many remain cancer-free during that time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Donafenib, oxaliplatin, fluorouracil, leucovorin
- What this could lead to
- If successful, this approach could offer a new way to delay or prevent liver cancer from returning after surgery in patients at high risk.
- What could go wrong
- This is a small, early-phase study with no comparison group, so results may not be definitive. The combination therapy also carries risks of side effects from chemotherapy and targeted drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIMETABOLITES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lei Zhang
Guangzhou, Guangdong, 51000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Pre-Surgery immunotherapy prime the immune system to fight head and neck cancer?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a simple belly press make liver cancer radiation more precise?
- Can a Heat-and-Freeze treatment plus a vaccine outsmart pancreatic cancer?
- Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
- A new way to read CT scans may predict which liver surgery patients will develop Life-Threatening failure